September 16, 2024 03:11 PM EDT

European regulators fortify single-arm trial advice, but underscore preference for placebo-controlled designs

Max Bayer

Pharma Reporter

The European Medicines Agency has solidified its recommendations to drugmakers that want to use single-arm designs in a pivotal trial, but emphasized that any such …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

European regulators fortify single-arm trial advice, but underscore preference for placebo-controlled designs

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Stem cell startup spun out of George Church’s lab raises $75M

Here's what today's Fed rate cut means for biotech, pharma and venture capital

FDA rejects Vanda’s treatment for digestion condition, company rebukes agency's actions

Edgewise’s stock surges as heart drug passes early safety test

Exclusive: Flagship-backed Valo Health loses interim CEO ahead of key Phase 2 readout

Breaking down silos with a new quantitative approach to drug development

Eu­ro­pean reg­u­la­tors for­ti­fy sin­gle-arm tri­al ad­vice, but un­der­score pref­er­ence for place­bo-con­trolled de­signs

Pharma Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

European regulators fortify single-arm trial advice, but underscore preference for placebo-controlled designs